Cited by 780HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Open access

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.·2018·Nature

DOI 10.1038/nature25475PMC PMC5808581

Open this paper in CoChat — free account

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature25475

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777

Flagged first, then by citations

Show all 54 references

1 of the 54 references couldn’t be matched to a known paper.

Sorted by citations

Items 601–700 of 779

Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms
Choucair, K., Chamseddine, S., Azmi, A. S., & Philip, P. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1769447 · Cited by 2
Antibody–drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology
Wang, H., Yan, X., Xia, C., Chen, D., Pan, B., Zhang, Y., & Zhang, Q. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1756741 · Cited by 2
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)
He, K., Forde, P. M., Govindan, R., Santoro, A., Gettinger, S. N., Borghaei, H., Spira, A., Chu, Q., Zinner, R., Schoenfeld, A. J., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106078 · Cited by 2
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs
Ballı, S., Başoğlu, T., & Ozdogan, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771869 · Cited by 2
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Zhang, X., Wang, Y., Cai, M., Wang, F., Xie, T., Ying, J., Sheng, W., Fan, X., Qu, X., Wang, C., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01804-8 · Cited by 3
Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence
Suleiman, A. A., Quagliariello, V., Spadafora, L., Russo, F. Y., & Maurea, N. (2026) · Pharmaceuticals · doi:10.3390/ph19060833 · Cited by 2
Molecular-driven treatment for biliary tract cancer: the promising turning point
Persano, M., Puzzoni, M., Ziranu, P., Pusceddu, V., Lai, E., Pretta, A., Donisi, C., Pinna, G., Spanu, D., Cimbro, E., et al. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1982699 · Cited by 2
Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non–Small-Cell Lung Cancer and Other Cancer Types
Yin, Y., Song, L., Shi, D., Liu, B., Li, X., Yang, M., Liu, B., Wang, D., & Qin, J. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00325 · Cited by 3
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
Li, H., Li, X., Lan, S., Zuo, X., Du, T., Liu, Y., Zhang, C., Zhu, J., & Cheng, Y. (2022) · Tumori Journal · doi:10.1177/03008916221101426 · Cited by 2
Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
Li, K., Bosdet, I., Yip, S. S. F., Ho, C., Laskin, J. J., Melosky, B. L., Wang, Y., & Sun, S. B. (2023) · Current Oncology · doi:10.3390/curroncol30080515 · Cited by 2
Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan
Chen, B.-F., Tsai, Y., Lien, P., Lin, Y., Feng, C.-J., Chen, Y.-J., Cheng, H.-F., Liu, C., Chao, T., Lai, J., et al. (2023) · Breast Cancer · doi:10.1007/s12282-023-01524-8 · Cited by 2
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high ( MSI ‐H) molecular subtype
Brodeur, M. N., Selenica, P., Ma, W., Moufarrij, S., Dagher, C., Basili, T., Abu‐Rustum, N. R., Aghajanian, C. A., Zhou, Q. C., Iasonos, A. E., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13698 · Cited by 2
Molecular and immunohistochemical characterization of ERBB2 activating mutations in low‐grade serous ovarian carcinoma
Neil, A. J., Nkosi, D., Yoon, J., Kolin, D. L., & Sholl, L. M. (2025) · Histopathology · doi:10.1111/his.15452 · Cited by 2
Molecular Recognition and Quantification of HER-3, HER-4 and HRG-α in Whole Blood and Tissue Samples Using Stochastic Sensors
Staden, R. S., & Gheorghe, D. (2022) · Micromachines · doi:10.3390/mi13101749 · Cited by 2
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 2
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer
Parmar, S. S., Keck, J. M., Kong, B. L., Look, R. M., Johnson, B., Patterson, J., Labrie, M., Guimarães, A. R., Corless, C. L., Beadling, C., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00183 · Cited by 2
Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test
Harada, Y., Sato, A., Araki, M., Matsumoto, S., Isaka, Y., Sagae, Y., Abe, T., Aoyagi, Y., Sueoka, E., Okuno, Y., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-021-00656-3 · Cited by 2
Molecular profiling leading to personalized treatment in breast cancer
Klocker, E. V., Balić, M., & Steger, G. G. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00792-4 · Cited by 2
Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma
King, D. A., Weiel, J. J., Reyes, R., Mills, M. A., Itchon, A., Fisher, G. A., Ford, J. M., & Suarez, C. J. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00093 · Cited by 2
Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study
Kondo, T., Kanai, M., Matsubara, J., Yamaguchi, D., Ura, T., Kou, T., Itani, T., Nomura, M., Funakoshi, T., Yokoyama, A., et al. (2023) · Medical Oncology · doi:10.1007/s12032-023-02011-y · Cited by 2
PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room
Raghav, K. P. S., Loree, J. M., & Kopetz, S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2580 · Cited by 2
Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma
Alhalabi, O., & Gao, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-71509-0_16 · Cited by 2
Precision in Cancer Pharmacogenomics
Kyrochristos, I. D., Baltagiannis, E. G., Mitsis, M. C., & Roukos, D. H. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0011 · Cited by 2
Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?
Grinda, T., & Pistilli, B. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101832 · Cited by 2
The Relationship Between Gene Mutations and the Clinicopathological Features and Prognosis of Gastric Cancer
Nie, Z., Zeng, K., Yan, Q., Liu, Y., Bian, Y., Zhu, J., Guo, Z., He, F., Shi, H. N., & Guo, Y. Q. (2023) · International Journal of Surgical Pathology · doi:10.1177/10668969231188421 · Cited by 1
A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells
Khorzoughi, S. B., Tavakoli, M., Mortazavi, M., Jafarnejad, Z., Malekpour, A., Malek, T. K., & Kargar, F. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2420202 · Cited by 1
Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20‐17/KM23 trial
Lee, K., Lee, K., Kim, D., Yoon, J., Choi, Y. J., Lee, S. H., Kim, J. W., Park, K. H., Choi, W., Lee, Y., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70026 · Cited by 1
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
Li, B. T., Gandhi, L., Ravichandran, V., Besse, B., Mazières, J., Shapiro, G. I., Boni, V., Waqar, S. N., Park, H., Quinn, D. I., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.09.009 · Cited by 1
Self-citation
Implementing a Molecular Tumor Board in Routine Clinical Practice: Four-Year Experience from a German Single Center
Kim, J. H., Park, S. W., & Lee, M. (2022) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/bbqgohwy2t · Cited by 1
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)
Kanemura, H., Tanizaki, J., Matsumoto, K., Masuishi, T., Isobe, T., Kenmotsu, H., Sunakawa, Y., Shimizu, T., Chiba, Y., Yamamoto, N., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116684 · Cited by 1
Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability
Ruiter, G., Le, X., Soo, R. A., Yamamoto, N., Girard, N., Wu, Y.-L., Sabari, J. K., & Nadal, E. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109378 · Cited by 1
Treatments for human epidermal growth factor receptor 2 (HER2)–altered cancers evaluated using a tumor‑agnostic approach: A narrative review
Harada, G., Chaft, J. E., Schram, A. M., Pavlakis, N., & Wu, Y.-L. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103137 · Cited by 1
Self-citation
THE FUTURE OF CANCER CURE: EXPLORING MEDICAL BREAKTHROUGHS AND REVOLUTIONARY TREATMENTS
Shankar, R., Gupta, V., Yadav, D. S., Amarnath, D. R., & , B. (2024) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v31i3.5279 · Cited by 1
New clinical trial design borrowing information across patient subgroups based on fusion-penalized regression models
Kerioui, M., Iasonos, A. E., Gönen, M., & Arfè, A. (2024) · Statistical Methods in Medical Research · doi:10.1177/09622802241267355 · Cited by 1
Targeting Tumorigenic Coactivators in the PI3K / AKT Signaling Pathway: A Novel Approach for Cancer Treatment
Haque, M. A., Poullikkas, T., Kaisar, F. M. A., Khan, A., Haque, S., Mollik, M., Mowa, M. J., Khatun, H., Mamun, A., & Bithy, M. B. A. (2025) · Cancer Medicine · doi:10.1002/cam4.71304 · Cited by 2
A Bayesian Latent Subgroup Design for Basket Trials with Survival Endpoints
Han, Y., & Shi, H. (2026) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2611817 · Cited by 1
Recent advances in HER2-targeted inhibitors for cancer therapy
Zhu, W., & Lu, X. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100127 · Cited by 1
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer
Lovly, C. M., Baik, C., Nagasaka, M., Patil, T., Maruti, S. S., Stanhope, S. A., Kaya, N. A., Herbertz, S., Nordstrom, B., Evans, K., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01272 · Cited by 1
In the literature: December 2019
Gambardella, V., Insa, A., Cejalvo, J. M., & Cervantes, A. M. R. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000642 · Cited by 1
ERBB3 deficiency causes a multisystemic syndrome in human patient and zebrafish
Liu, K., Chen, R., Zhang, M., Gong, Y., Wang, Y., & Cai, W. (2023) · Clinical Genetics · doi:10.1111/cge.14462 · Cited by 1
RACK1 promotes the occurrence and progression of cervical carcinoma
Yang, D., Lu, X., Zhang, X., Zhang, X., Zhu, L., & Liu, Q. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.25012 · Cited by 1
Molecular Pathology of Breast Tumors
Ross, D. S., & Pareja, F. G. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.001 · Cited by 1
Understanding mechanisms of resistance to HER2-targeted therapies in HER2-positive breast cancer
Nakajima, H., & Mukohara, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00011-7 · Cited by 1
Case report: Pyrotinib and tegafur combined with radiotherapy achieved notable response in HER2-amplified rectal cancer with multiple metastases after multiline treatments
Huang, P., Wen, F., & Wang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1431542 · Cited by 1
Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies
Pérez, C. G., Aras, E. L., Saiz-López, P., García-Toro, E., Abad, C. B., Ledesma, I. R., González, M. P., Domínguez, M. V., Cabria, N. E., & Herrero, G. C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03651-w · Cited by 1
Promising Response to Pyrotinib in Non-Small-Cell Lung Cancer with the Rare HER2 R456C Mutation: A Case Report
Wang, Y., Hu, J., Liu, R., Li, P., Wang, L., & Yang, G. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096371951250409093625 · Cited by 1
Molekularpathologie zur Prädiktion von Prognose und Therapie bei Tumorerkrankungen
Röcken, C. (2019) · Der Onkologe · doi:10.1007/s00761-019-0640-z · Cited by 1
Cancer bronchique non à petites cellules avec anomalies moléculaires actionnables (KRAS, BRAF, MET, fusions)
Abdayem, P., & Planchard, D. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00107-5 · Cited by 1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Simon, E., Abdayem, P., Planchard, D., & Greillier, L. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00120-3 · Cited by 1
Precise Predictive and Therapeutic Strategy for Breast Cancer
Kyrochristos, I. D., Peristeri, D. V., Ziogas, D. E., Lykoudis, E. G., & Roukos, D. H. (2018) · Future Oncology · doi:10.2217/fon-2018-0277 · Cited by 1
Learning All That We Can From MyPathway
Tao, J. J., Schram, A. M., Harding, J. J., Drilon, A. E. D. C., & Hyman, D. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.4728 · Cited by 1
Self-citation
Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant CancersPreprint
Sudhan, D. R., Zotano, Á. G., Won, H. H., Ericsson, P. I. G., Servetto, A., Lee, K., Formisano, L., Guo, Y. P., Liu, Q., Kinch, L. N., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3362256 · Cited by 1
Self-citation
HER2 in Breast Cancer
Annaratone, L., Sarotto, I., & Marchiò, C. (2019) · Encyclopedia of pathology · doi:10.1007/978-3-319-62539-3_4710 · Cited by 1
Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic ImplicationsPreprint
Nguyen, T. T., Hamdan, D., Angeli, E., Le, Q., Pamoukdjian, F., & Bousquet, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4133612 · Cited by 1
VHL loss enables immune checkpoint blockade therapy by boosting type I interferon responsePreprint
Jiao, M., Bao, X., Hu, M., Pan, D., Liu, X., Kim, J., Li, F., & Li, C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.28.569047 · Cited by 1
Construction of a CT Radiomics Model for Predicting Her2 Expression in Bladder Cancer Based on Random Forest AlgorithmPreprint
Zhang, G., Chen, Z., Xia, W., Wang, Y., Ni, Z., Xue, B., Zhao, W., & Liu, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4515456/v1 · Cited by 1
Contrastive Learning for Graph-Based Biological Interaction Discovery: Insights from Oncologic PathwaysPreprint
Nguyen, P.-N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.23.604746 · Cited by 1
The Future Is Today
Peiper, S. C., & Ehrlich, G. D. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0107
Wenig neue Marker für die Therapiestrategie
Braitmaier, H. (2018) · Onkologische Welt · doi:10.1055/s-0038-1670947
Targeted RNA NextGenSeq profiling in oncology using single molecule molecular inversion probesPreprint
Lenting, K., van den Heuvel, C. N. A. M., van Ewijk, A., Tindall, E. A., Ge, W., Küsters, B., Dorsthorst, M. T., ter Laan, M., Huynen, M. A., & Leenders, W. P. J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/440065
Breakthrough Cancer Genome Analysis in time and Space: Novel Oncotargets and Early Drug Development
Kyrochristos, I. D., Ziogas, D. E., Antoniou, P., Mitsis, M. C., Lykoudis, E. G., & Roukos, D. H. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0141
Precision in Personalized Prediction-Based Medicine
Kyrochristos, I. D., Ziogas, D. E., & Roukos, D. H. (2018) · Personalized Medicine · doi:10.2217/pme-2018-0079
Novel Agents for the Management of Endocrine Resistant Breast Cancer
Reid, S., & Mayer, I. A. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0298-3
Self-citation
CBNPC et autres cibles thérapeutiques (BRAF, HER2, MET, RET, NTRK...)
Percin, S. D., & Planchard, D. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30042-9
SUMMIT
Luscan, A., & Pasmant, É. (2018) · médecine/sciences · doi:10.1051/medsci/2018232
Targeting HER2 in Lung Cancer
Bulbul, A., Leal, A., & Husain, H. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_6
GI Including GIST
Vakiani, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_7
[CT guided percutaneous needle biopsy of mediastinal lymph nodes for staging of primary lung carcinoma].
Akamatsu, H., AMANO, J., Suzuki, A., & Kikushima, Y. (1994) · PubMed
Production of the Extracellular Part of the ErbB2 Receptor for the Study of Immunobiologicals
Rybchenko, V. S., Сергеевич, Б. Д., Панина, А. А., Солопова, О. Н., Yakimov, S. A., Aliev, T. K., Dolgikh, D. A., & Kirpichnikov, M. P. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s106816202003019x
Development of HER2 -targeted Therapies for Gastrointestinal Cancer
Sawada, K., Nakamura, Y., & Shitara, K. (2020) · European Oncology & Haematology · doi:10.17925/eoh.2020.16.1.29
[Global research hotspots on oncology-bibliometric analysis based on the ESI hot papers].
Han, X., Li, X., Gong, X., Li, B., Bai, B., Zhang, L., Pu, J. Y., Li, Y., & Zhang, M. (2020) · PubMed · doi:10.7507/1001-5515.202009083
Self-citation
Building bridges between drug development and cancer science: a tribute to José Baselga's legacy
Hyman, D. M., Soria, J., & Tabernero, J. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.209
Self-citation
Agnostische Tumortherapie – was ist das?
Schmidt, M., Hönig, A., Denkert, C., & Desuki, A. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04788-3
HER2 G776S Mutation Promotes Oncogenic Potential in Colorectal Cancer Cells when Accompanied by Loss of APC FunctionPreprint
Mitani, Y., Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Mizumoto, A., Yamamoto, Y., Saito, T., Kataoka, S., Matsubara, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-594302/v1
Expert Discussion: HER2-Positive Breast Cancer
Foukakis, T., Matikas, A., Oikonomidou, O., Andreopoulou, E., & Mavroudis, D. (2021) · Breast Care · doi:10.1159/000516965
Genomics-based Precision Medicine for Patients with Cancer
van de Haar, J. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/946
Modeling HER2 Mutations in Colorectal Cancer using a HER2 Transgenic Mouse Model and Gastrointestinal Organoids
Murray, E. M. (2021) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/xjje-vr62
Nuevo Museo para Galería de Arte, Perm (Rusia)
Bernaskoni, B., Hadid, Z., Acconci, V., Architects, A., Ruskeepää, E., Lindgren, T., & Arkitekter, S. R. L. (2008) · Dialnet (Universidad de la Rioja)
Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review
Luo, Y., Yao, B. W., Huang, P. C., Zhao, Y., & Chen, J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-3468
Genomic Applications in Breast Carcinoma
Pareja, F. G., Mattos‐Arruda, L. D., Weigelt, B., & Reis-Filho, J. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_26
Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren
Dittrich, C. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_389-1
Faculty Opinions recommendation of Genomic profile of advanced breast cancer in circulating tumour DNA.
Carroll, J. S. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739985691.793585094
Tumor genetics and individualized therapy
Hlevnjak, M. (2022) · Die Gynäkologie · doi:10.1007/s00129-022-04931-8
Novel Therapies
Niglio, S. A., & Galsky, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-70646-3_26
Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras)
Groves, E., Haris, N. R. M., & Greystoke, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00002-0
Breast
Ross, D. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_8
Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report
di Mauro, P., Capici, S., Cogliati, V., Pepe, F. F., Maggioni, C., Riva, F., Cicchiello, F., & Cazzaniga, M. E. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100167
Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report
Zeng, D., Zhao, X., Di, L., Lou, L., Song, Y., Zhang, Y., Liu, H., & Li, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.918297
Molecularly Targeted Therapy in Cholangiocarcinoma
Desai, A. P., & Borad, M. J. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_22
HER2-Activating Missense Mutations in Advanced Non-Small Cell Lung Cancer: Rare But Targetable Spot Should Not Be NeglectedPreprint
Yang, G., Yang, Y., Liu, R., Hu, J., Xu, H., Li, W., Hao, X., & Wang, Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155240
Personalisierte Therapie bei fortgeschrittenen/metastasierten Mammakarzinomen: Biomarker für ein längeres Überleben
Boxberg, M., Grill, S., & Poremba, C. (2022) · Trillium Diagnostik · doi:10.47184/td.2022.01.05
Genomics of breast cancer brain metastases: a meta-analysis and therapeutic implicationsPreprint
Nguyen, T. T., Hamdan, D., Angeli, E., Le, Q., Pamoukdjian, F., & Bousquet, G. (2022) · Research Square · doi:10.21203/rs.3.rs-2364912/v1
QuantAnts machines discover biomarkers for RAS signaling activation and design sgRNAs for CRISPR to target complex CD9, CD34, and CD74.Preprint
Nguyen, N. (2022) · Research Square · doi:10.21203/rs.3.rs-2347890/v1
A Look at Emerging Therapeutic Targets for Gallbladder Cancer: A Multi-Omics Approach
Baichan, P., Naicker, P., Devar, J. W., Smith, M., & Nweke, E. E. (2023) · Springer eBooks · doi:10.1007/978-981-19-6442-8_10
Data from Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Meric‐Bernstam, F., Johnson, A. M., Dumbrava, E. E. I., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon, J. A., & Piha-Paul, S. A. (2023) · doi:10.1158/1078-0432.c.6528374.v1
Self-citation
Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Kalra, R., Chen, C. H., Wang, J., Salam, A. B., Dobrolecki, L. E., Lewis, A. N., Sallas, C., Yates, C. C., Gutiérrez, C., Karanam, B., et al. (2023) · doi:10.1158/0008-5472.c.6514088.v1
Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Meric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · doi:10.1158/1078-0432.c.6533210.v1
Self-citation
Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Jhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2023) · doi:10.1158/1078-0432.22479515
Self-citation
Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Jhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2023) · doi:10.1158/1078-0432.c.6530237
Self-citation
Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
Manning‐Geist, B. L., Liu, Y. L., Devereaux, K. A., Paula, A. D. C., Zhou, Q. C., Ma, W., Selenica, P., Ceyhan‐Birsoy, O., Moukarzel, L. A., Hoang, T. J., et al. (2023) · doi:10.1158/1078-0432.c.6532995

Authors: Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Vall d'Hebron Hospital Universitari (ES)
Dana-Farber Cancer Institute (US)
USC Norris Comprehensive Cancer Center (US)
Vanderbilt University (US)
Peter MacCallum Cancer Centre (AU)
Washington University in St. Louis (US)
Puma Biotechnology (United States) (US)
Corresponding author: Hyman, David M.
ORCID: Hyman, David M.
Piha-Paul, Sarina A.
Won, Helen
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Juric, Dejan
Quinn, David I.
Mayer, Ingrid A.
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Erinjeri, Joseph P.
Scaltriti, Maurizio
Ulaner, Gary A.
Patel, Juber
Bouvier, Nancy
Murali, Rajmohan
Schram, Alison M.
Smyth, Lillian M.
Jhaveri, Komal
Li, Bob T.
Drilon, Alexander
Harding, James J.
Iyer, Gopa
Taylor, Barry S.
Berger, Michael F.
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Arteaga, Carlos L.
Solit, David B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-01-31
Volume: 554
Issue: 7691
Pages: 189-194
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature25475
PMC: PMC5808581
OpenAlex: W2785610956
Cited by: 780
References: 54
Citations by year: 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
FWCI: 34.53
Type: journal article
Language: en
Update notices: correction (2019-02-12)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: Puma Biotechnology
National Institutes of Health (UL1TR000371)
National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks